论文部分内容阅读
Objective Background The study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab(PemPBev)and paclitaxel/carboplatin/bevacizumab(PacCBev)as first-line therapy for advanced nonsquamous non-small cell lung cancer(NS-NSCLC)patients with wild-type driver genes in a real-world setting.